Our first edition of the Sector Snapshot provides a review of sector data from 2022, an outlook for 2023 and beyond, and highlights how gene editing is shaping the sector.
A look into the landscape and gap analysis of the workforce needed for sustainable biomanufacturing of cell and gene therapies in the United States.
Clinical milestones, regulatory developments, and patient impact steadily advance for the cell and gene sector.
Regenerative medicine takes aim at cancer and a wide range of other prevalent and rare diseases.
The global cell & gene therapy sector is on pace for annual records in product approvals and financings.
Sector financing reached $19.9B in 2020, doubling from the previous year; 2021 is likely to be a record year for the number of regulatory decisions on new regenerative medicine products
ARM’s Q3 2020 Trend Talk
Global financing for the regenerative medicine sector set an annual record of $15.9 billion through just the first three quarters of 2020, according to data released by ARM. Despite the COVID-19 pandemic, financing for the cell, gene, and tissue-based therapies sector surpassed the previous record of $13.5 billion set during full-year 2018.
This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.